• Study Resource
  • Explore
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
Works Cited
Works Cited

... This journal article focuses on the fact that even though the symptoms of Alzheimer’s do not show up until around age 60, the actual changes in the brain start as early as age 40. This article ...
Alzheimer’s disease in family practice CPD Article: Abstract
Alzheimer’s disease in family practice CPD Article: Abstract

... It is estimated that 10–15% of individuals over the age of 65 years suffer from some form of dementia and this incidence rises to 20% in individuals over the age of 80 years. Of those affected at present, 55% suffer from SDAT and 15% from multi-infarct dementia. Some 22% suffer from mixed forms of d ...
Cognitive Disorders
Cognitive Disorders

... Develops slowly 80% Irreversible Progressive deterioration  Multiple Cognitive Deficits Impaired short & long term memory Aphasia: ↓Language Apraxia: ↓ Motor function Agnosia: Inability to recognize objects ↓ Abstract Thinking ...
Occupational Therapy Assistant
Occupational Therapy Assistant

... If I had to do this all over again, I would possibly mix in the elderly with Alzheimer’s in my research paper since I plan to work with both now.  I feel like I will take a lot of information from this project with me to college. I believe what benefited me the most was job shadowing and learning ...
No Slide Title
No Slide Title

... Namenda, Axura and Ebixa (memantine), is an N-methyl D-aspartate (NMDA) antagonist for the treatment of moderate to severe AD. The medication may allow patients to maintain daily functions a little longer. For example, Memantine may help a patient in the later stages of AD maintain his or her abilit ...
Baxter Announces Topline Results Of Phase III Study of
Baxter Announces Topline Results Of Phase III Study of

... score (lower scores indicating greater impairment) in activities such as eating, walking, grooming, and dressing. The 3MS is a widely used test for dementia based on the MiniMental State Examination (MMSE), but incorporates four added test items, more graded scoring, and some other modifications tha ...
RSNA Statement on Imaging in the Evaluation of Dementia
RSNA Statement on Imaging in the Evaluation of Dementia

... This statement was prepared in collaboration with the American Society of Neuroradiology. The RSNA strives to be an objective advocate for patient care, and provides these evidence-based recommendations to help guide patients and their physicians in the most beneficial use of imaging examinations. R ...
AIM PET/CT criteria check list for Alzheimer`s scans
AIM PET/CT criteria check list for Alzheimer`s scans

... The patient has had a comprehensive clinical evaluation which has included: A comprehensive medical history including an assessment of activities of daily living from a well-acquainted informant other than the patient; A physical and mental status examination formally documenting the patient’s cogni ...
Dear Colleague - North Carolina Medical Society
Dear Colleague - North Carolina Medical Society

... Patients with HD often have complex behavioral and motor problems. Families face difficult problems with finances, patient care, and placement. The NC-CCCHD can help get them the care and medications they need. It also can get your patients and families with HD linked up with clinical trials that st ...
Activities for Mid Stage Alzheimer`s
Activities for Mid Stage Alzheimer`s

... contains our short-term memory center. This is the first part of the brain to be affected by Alzheimer's. However the disease is not localized here. It will travel to all parts of the brain. That is what makes Alzheimer's disease different from other diseases. ...
Huntington`s disease (HD) results from genetically
Huntington`s disease (HD) results from genetically

... Huntington's disease (HD) results from genetically programmed degeneration of brain cells, called neurons, in certain areas of the brain. This degeneration causes uncontrolled movements, loss of intellectual faculties, and emotional disturbance. HD is a familial disease, passed from parent to child ...
ACE Inhibition: 25 Years of Progress From Hypertension and Heart
ACE Inhibition: 25 Years of Progress From Hypertension and Heart

... cardiovascular disease. In clinical practice, the same patient selection criteria and treatment regimens should be observed as in the clinical trials to maximize patient benefits and avoid undue harms. It should not be assumed that all drugs within a class are interchangeable. For most cardiovascula ...
World Alzheimer`s Day - September 21
World Alzheimer`s Day - September 21

... importance to look for reversible causes such as thyroid problems, neurological conditions, nutritional deficiencies, etc. There is no drug which can reverse the process, but progression and worsening may be prevented. Vitamin supplements are given to correct nutritional problems. Medications are av ...
Huntington's Disease - Bridgewater College
Huntington's Disease - Bridgewater College

... Family history of Huntington's disease, you may want to talk with ...
Amber: Chronic Illness
Amber: Chronic Illness

...  Affects almost ½ of people over 85 in US  Definitive diagnosis via autopsy ►Behavioral ...
Cellular and molecular mechanisms of brain aging
Cellular and molecular mechanisms of brain aging

... Animal studies-------------------+/- ...
March 2013 Monitoring International Trends
March 2013 Monitoring International Trends

... when compared with the use of two other therapies approved in the US for the acute treatment of HAE, Firazyr and Kalbitor f) A team from the University of Michigan Medical School has found that an antidepressant drug used for decades - tranylcypromine, or TCP - may be useful in treating sickle cell ...
Grifols` Alzheimer research strategy addresses the degenerative
Grifols` Alzheimer research strategy addresses the degenerative

... peptides (Aß) 17, 40 and 42, three of the more frequently found proteins in blood, which could be considered as potential biomarkers for preclinical diagnosis of Alzheimer's disease. Grifols is also currently conducting different clinical studies with more than 400 participants in order to obtain da ...
Native Son`s Hall - Alzheimer Society of Canada
Native Son`s Hall - Alzheimer Society of Canada

... Minds in Motion® is designed for people diagnosed with Alzheimer’s disease or another dementia and a friend, family member or care partner. Enjoy light exercise conducted by a certified fitness instructor, followed by activities or games and social time in a relaxed atmosphere. Light refreshments wi ...
Human Brain Deficits of PKCe
Human Brain Deficits of PKCe

... Neurosciences Institute (BRNI) announced findings from a new study entitled, “PKCe Deficits in Alzheimer’s Disease Brains and Skin Fibroblasts.” These new findings offer significant promise for a new therapeutic and diagnostic approach to Alzheimer's disease (AD) that has remained so refractory to e ...
update on alzheimer`s disease clinical trials
update on alzheimer`s disease clinical trials

... whether there is a “critical window” for anti-Aβ therapy within the preclinical stages of AD • To develop more sensitive outcome measures to improve ...
Article - Crest Physical Therapy
Article - Crest Physical Therapy

... accepting their fate in the face of a condition we know to be fatal.Without a known, truly effective treatment available, as of yet, pursuing an FDA-approved clinical trial investigating a possible treatment for Alzheimer’s disease would seem to be a reasonable course of action for an individual. Wh ...
View/Download PDF
View/Download PDF

... patient’s own dendritic cells (DC) from their blood, modify the cells through the use of small interfering oligonucleotides, and vaccinate the patient by injection of these modified cells under the skin with a small needle. The cells are absorbed, trafficked to the pancreatic lymph nodes, and thereb ...
< 1 ... 67 68 69 70 71

Alzheimer's disease research

In April 2014 there were 315 open clinical trials under way to understand and treat Alzheimer's disease. 42 of these studies were open, human phase three trials, the last step before United States Food and Drug Administration (FDA) approval and marketing.There are different approaches. One approach is to reduce amyloid beta, for example with bapineuzumab, an antibody in phase III studies for patients in mild to moderate stage; semagacestat, a γ-secretase inhibitor, MPC-7869; and acc-001 or CAD106, vaccines against amyloid beta. Other approaches are neuroprotective agents, like AL-108 (phase II completed); or metal-protein interaction attenuation, as is the case of PBT2 (phase II completed). Yet another approach is to use general cognitive enhancers, as may be the case for memantine, a pharmaceutical approved in the United States and European Union to treat moderate-to-severe AD. A recent (March 2015) physical approach utilizes ultrasound for penetrating the blood-brain barrier and activating microglial cells, in experimental animals; researchers reported in Science that the essay eliminates a great proportion of amyloid beta and restores memory function. Finally, there are basic investigations on the origin and mechanisms of Alzheimer's disease.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report